efavirenz Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals	989	154598-52-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: efavirenz stocrin (-)-Efavirenz sustiva	Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta are not inhibited by efavirenz. Molecular weight: 315.68 Formula: C14H9ClF3NO2 CLOGP: 3.73 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 38.33 ALOGS: -4.57 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

efavirenz
stocrin
(-)-Efavirenz
sustiva

Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta are not inhibited by efavirenz.

Molecular weight: 315.68
Formula: C14H9ClF3NO2
CLOGP: 3.73
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 38.33
ALOGS: -4.57
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	27.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	42.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Sept. 17, 1998	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Maternal exposure during pregnancy	862.79	22.85	474	10066	155165	53183361
Abortion spontaneous	789.94	22.85	309	10231	46326	53292200
Stillbirth	621.82	22.85	163	10377	6634	53331892
Viral mutation identified	556.97	22.85	119	10421	1955	53336571
Virologic failure	518.71	22.85	114	10426	2150	53336376
Abortion induced	477.97	22.85	147	10393	10679	53327847
Pregnancy	464.30	22.85	189	10351	31252	53307274
Exposure during pregnancy	423.09	22.85	278	10262	124582	53213944
Immune reconstitution inflammatory syndrome	406.53	22.85	115	10425	6231	53332295
Foetal exposure during pregnancy	364.63	22.85	164	10376	34551	53303975
Drug resistance	304.74	22.85	123	10417	19839	53318687
Normal newborn	268.78	22.85	86	10454	7093	53331433
Pathogen resistance	268.03	22.85	84	10456	6476	53332050
Congenital umbilical hernia	212.64	22.85	42	10498	455	53338071
Live birth	167.03	22.85	74	10466	14985	53323541
Blood HIV RNA increased	164.86	22.85	37	10503	768	53337758
Lipodystrophy acquired	157.62	22.85	41	10499	1609	53336917
Caesarean section	141.90	22.85	69	10471	17251	53321275
Birth mark	128.60	22.85	24	10516	187	53338339
Premature delivery	110.15	22.85	67	10473	26037	53312489
Treatment noncompliance	95.73	22.85	67	10473	32968	53305558
Fanconi syndrome acquired	94.31	22.85	25	10515	1056	53337470
Lactic acidosis	92.97	22.85	69	10471	37184	53301342
Pregnancy with implant contraceptive	91.95	22.85	29	10511	2277	53336249
Viral load increased	91.09	22.85	26	10514	1449	53337077
Cerebellar ataxia	83.70	22.85	22	10518	899	53337627
Pulmonary tuberculosis	81.08	22.85	32	10508	4849	53333677
Immune reconstitution inflammatory syndrome associated tuberculosis	79.02	22.85	18	10522	400	53338126
Pregnancy on contraceptive	72.59	22.85	21	10519	1228	53337298
Autoimmune hepatitis	70.70	22.85	34	10506	8284	53330242
Foetal death	61.17	22.85	32	10508	9315	53329211
CD4 lymphocytes decreased	58.02	22.85	19	10521	1682	53336844
Drug interaction	56.51	22.85	130	10410	219199	53119327
Ataxia	54.99	22.85	35	10505	14702	53323824
Premature baby	54.65	22.85	39	10501	19762	53318764
Ectopic pregnancy	52.42	22.85	20	10520	2767	53335759
Malaria	51.87	22.85	12	10528	286	53338240
Pain	51.70	22.85	26	10514	588372	52750154
Hepatitis fulminant	50.72	22.85	21	10519	3598	53334928
Cleft lip and palate	48.88	22.85	12	10528	371	53338155
Anaemia	48.58	22.85	142	10398	276576	53061950
Tuberculosis	45.61	22.85	28	10512	11043	53327483
Portal hypertension	43.51	22.85	19	10521	3709	53334817
Twin pregnancy	42.79	22.85	14	10526	1235	53337291
Cholestatic liver injury	40.46	22.85	16	10524	2435	53336091
Drug level increased	40.43	22.85	33	10507	20388	53318138
Mitochondrial cytopathy	40.07	22.85	10	10530	331	53338195
Lipoatrophy	39.90	22.85	10	10530	337	53338189
Rash maculo-papular	38.85	22.85	38	10502	29711	53308815
Fatigue	36.65	22.85	55	10485	730451	52608075
Premature rupture of membranes	35.45	22.85	18	10522	4922	53333604
Hepatomegaly	34.26	22.85	24	10516	11807	53326719
Nephropathy toxic	33.58	22.85	21	10519	8551	53329975
Arthralgia	33.51	22.85	23	10517	439760	52898766
Encephalopathy	32.15	22.85	38	10502	36770	53301756
Abnormal dreams	31.85	22.85	22	10518	10579	53327947
Congenital anomaly	31.84	22.85	12	10528	1605	53336921
Cytomegalovirus chorioretinitis	31.61	22.85	12	10528	1637	53336889
Cardiac malposition	31.18	22.85	6	10534	56	53338470
Gene mutation	30.73	22.85	11	10529	1272	53337254
Abdominal discomfort	30.19	22.85	4	10536	221058	53117468
Abortion threatened	29.69	22.85	9	10531	619	53337907
HIV-associated neurocognitive disorder	29.53	22.85	7	10533	186	53338340
Hepatic displacement	28.22	22.85	5	10535	28	53338498
Joint swelling	28.17	22.85	6	10534	234632	53103894
Maternal drugs affecting foetus	28.01	22.85	16	10524	5530	53332996
Retinal toxicity	27.69	22.85	10	10530	1187	53337339
Spinocerebellar disorder	27.26	22.85	5	10535	35	53338491
Meningitis cryptococcal	26.80	22.85	10	10530	1301	53337225
Pregnancy on oral contraceptive	26.31	22.85	10	10530	1369	53337157
Diastasis recti abdominis	26.15	22.85	5	10535	45	53338481
Pre-eclampsia	26.11	22.85	18	10522	8629	53329897
Hypertriglyceridaemia	26.11	22.85	16	10524	6288	53332238
HIV infection	25.92	22.85	8	10532	584	53337942
Isosporiasis	25.76	22.85	5	10535	49	53338477
Genital prolapse	25.76	22.85	5	10535	49	53338477
Type III hyperlipidaemia	25.73	22.85	4	10536	8	53338518
Peripheral swelling	25.29	22.85	5	10535	206103	53132423
Polydactyly	24.37	22.85	7	10533	399	53338127
Congenital acrochordon	24.19	22.85	5	10535	69	53338457
Multiple-drug resistance	23.84	22.85	12	10528	3223	53335303
Nightmare	23.78	22.85	23	10517	17728	53320798
Drug ineffective	23.53	22.85	83	10457	817162	52521364
Hydrocephalus	23.52	22.85	14	10526	5222	53333304
Acute stress disorder	23.29	22.85	6	10534	226	53338300

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Depression	994.41	14.76	682	21112	96378	32395354
Immune reconstitution inflammatory syndrome	850.73	14.76	297	21497	9262	32482470
Virologic failure	650.63	14.76	194	21600	3593	32488139
Viral mutation identified	626.11	14.76	179	21615	2840	32488892
Drug interaction	594.56	14.76	728	21066	217457	32274275
Lipodystrophy acquired	539.92	14.76	167	21627	3515	32488217
Pathogen resistance	441.82	14.76	184	21610	9326	32482406
Abnormal dreams	284.82	14.76	131	21663	8433	32483299
Drug resistance	259.09	14.76	172	21622	22793	32468939
Mitochondrial toxicity	254.14	14.76	87	21707	2543	32489189
Foetal exposure during pregnancy	229.84	14.76	203	21591	41098	32450634
Progressive external ophthalmoplegia	202.53	14.76	62	21732	1256	32490476
Eyelid ptosis	172.50	14.76	81	21713	5461	32486271
Loss of personal independence in daily activities	157.44	14.76	136	21658	26697	32465035
Lipoatrophy	149.65	14.76	42	21752	619	32491113
Congenital umbilical hernia	141.39	14.76	38	21756	472	32491260
Viral load increased	133.03	14.76	57	21737	3093	32488639
CD4 lymphocytes decreased	127.93	14.76	50	21744	2140	32489592
Pulmonary tuberculosis	125.39	14.76	63	21731	4926	32486806
Osteoporosis	110.85	14.76	80	21714	12102	32479630
Hyperlipidaemia	106.95	14.76	84	21710	14427	32477305
Fanconi syndrome acquired	106.35	14.76	44	21750	2186	32489546
Treatment failure	101.28	14.76	128	21666	39035	32452697
Gynaecomastia	96.83	14.76	65	21729	8754	32482978
Diplopia	96.30	14.76	79	21715	14433	32477299
Retinal toxicity	90.71	14.76	26	21768	415	32491317
Psychiatric decompensation	90.14	14.76	35	21759	1471	32490261
Depression suicidal	88.97	14.76	34	21760	1368	32490364
Tearfulness	85.91	14.76	35	21759	1671	32490061
HIV infection	85.13	14.76	36	21758	1890	32489842
Blood HIV RNA increased	84.27	14.76	34	21760	1583	32490149
Renal tubular disorder	84.03	14.76	49	21745	5153	32486579
Meningitis cryptococcal	80.38	14.76	36	21758	2173	32489559
Hyperlactacidaemia	71.94	14.76	37	21757	3037	32488695
Off label use	70.77	14.76	61	21733	306259	32185473
Paranoia	67.92	14.76	57	21737	10742	32480990
Nightmare	67.76	14.76	62	21732	13104	32478628
Treatment noncompliance	67.29	14.76	87	21707	27115	32464617
Kaposi's sarcoma	65.63	14.76	25	21769	997	32490735
Extraocular muscle paresis	64.57	14.76	21	21773	521	32491211
Ophthalmoplegia	63.73	14.76	27	21767	1424	32490308
Hepatic fibrosis	60.88	14.76	35	21759	3583	32488149
Death	58.19	14.76	105	21689	382412	32109320
Fanconi syndrome	57.86	14.76	27	21767	1793	32489939
Pneumonia	57.23	14.76	94	21700	355158	32136574
Hypertriglyceridaemia	54.79	14.76	46	21748	8673	32483059
Immune reconstitution inflammatory syndrome associated tuberculosis	53.87	14.76	18	21776	487	32491245
Proteinuria	50.12	14.76	60	21734	17295	32474437
Birth mark	48.35	14.76	14	21780	232	32491500
Nephropathy toxic	47.81	14.76	49	21745	11897	32479835
Tuberculosis	46.67	14.76	42	21752	8687	32483045
Fall	46.54	14.76	38	21756	196163	32295569
Febrile neutropenia	45.47	14.76	12	21782	119554	32372178
Renal impairment	45.21	14.76	150	21644	91822	32399910
Genotype drug resistance test positive	43.31	14.76	22	21772	1759	32489973
Depressive symptom	42.43	14.76	22	21772	1836	32489896
Hypophosphataemia	42.20	14.76	40	21754	8835	32482897
Drug abuse	42.19	14.76	3	21791	80240	32411492
Atrial fibrillation	42.00	14.76	13	21781	116691	32375041
Hypotension	41.88	14.76	50	21744	216060	32275672
HIV-associated neurocognitive disorder	41.86	14.76	14	21780	380	32491352
Multiple-drug resistance	41.85	14.76	28	21766	3747	32487985
Nervous system disorder	41.27	14.76	49	21745	14000	32477732
Malignant neoplasm progression	41.08	14.76	3	21791	78493	32413239
Blood triglycerides increased	39.70	14.76	49	21745	14570	32477162
Lactic acidosis	39.12	14.76	76	21718	33460	32458272
Glycosuria	38.87	14.76	19	21775	1399	32490333
Hydrocele	38.72	14.76	22	21772	2202	32489530
Dyslipidaemia	38.54	14.76	34	21760	6849	32484883
Portal hypertension	37.67	14.76	27	21767	4037	32487695
Drug-induced liver injury	37.66	14.76	62	21732	24001	32467731
Retroviral rebound syndrome	36.82	14.76	7	21787	13	32491719
Skull malformation	36.75	14.76	13	21781	419	32491313
Psychomotor skills impaired	36.31	14.76	22	21772	2481	32489251
Constipation	35.94	14.76	20	21774	126353	32365379
Polydactyly	35.08	14.76	17	21777	1228	32490504
Lymph node tuberculosis	34.69	14.76	13	21781	495	32491237
Osteopenia	33.51	14.76	27	21767	4805	32486927
CD4 lymphocytes abnormal	33.47	14.76	9	21785	112	32491620
Mycobacterium avium complex infection	33.22	14.76	22	21772	2895	32488837
Blood lactic acid increased	33.14	14.76	30	21764	6251	32485481
Hepatitis	33.05	14.76	58	21736	23635	32468097
Psychotic disorder	32.95	14.76	57	21737	22963	32468769
Suicidal ideation	32.50	14.76	76	21718	38007	32453725
Aspartate aminotransferase increased	32.31	14.76	108	21686	66321	32425411
Pain	31.64	14.76	48	21746	187508	32304224
Cytomegalovirus chorioretinitis	31.21	14.76	23	21771	3589	32488143
Acquired immunodeficiency syndrome	31.14	14.76	12	21782	494	32491238
Lymphadenopathy	31.13	14.76	61	21733	27021	32464711
Testicular germ cell tumour mixed	31.01	14.76	7	21787	39	32491693
Hepatosplenomegaly	29.62	14.76	23	21771	3880	32487852
Dyspnoea	29.37	14.76	134	21660	361911	32129821
Hepatic cirrhosis	28.61	14.76	45	21749	16764	32474968
Developmental hip dysplasia	28.61	14.76	10	21784	311	32491421
Mycobacterium avium complex immune restoration disease	28.39	14.76	7	21787	60	32491672
Fatigue	28.32	14.76	130	21664	350571	32141161
Gamma-glutamyltransferase increased	28.00	14.76	63	21731	30719	32461013
Neurosyphilis	27.89	14.76	7	21787	65	32491667
Hepatitis B	27.18	14.76	27	21767	6314	32485418
Hepatitis C	27.01	14.76	39	21755	13479	32478253
Vanishing bile duct syndrome	26.95	14.76	12	21782	714	32491018
Cryptococcosis	26.92	14.76	17	21777	2063	32489669
Hepatotoxicity	26.53	14.76	47	21747	19290	32472442
Cachexia	26.36	14.76	28	21766	7081	32484651
Osteonecrosis	26.24	14.76	43	21751	16579	32475153
Malaria	25.74	14.76	9	21785	280	32491452
Peripheral swelling	25.70	14.76	7	21787	68338	32423394
Anal cancer	25.17	14.76	10	21784	447	32491285
Renal tubular dysfunction	24.94	14.76	10	21784	458	32491274
Histoplasmosis disseminated	24.72	14.76	13	21781	1117	32490615
Megakaryocytes increased	24.70	14.76	6	21788	48	32491684
Diabetes mellitus	24.27	14.76	76	21718	45097	32446635
Night blindness	24.24	14.76	8	21786	208	32491524
Mitochondrial cytopathy	24.10	14.76	8	21786	212	32491520
Osteomalacia	23.84	14.76	12	21782	941	32490791
Alanine aminotransferase increased	23.83	14.76	110	21684	78369	32413363
Psychomotor retardation	23.71	14.76	18	21776	2937	32488795
Intracranial pressure increased	23.71	14.76	20	21774	3793	32487939
Talipes	23.43	14.76	15	21779	1863	32489869
Drug ineffective	23.38	14.76	156	21638	383321	32108411
Infection	23.22	14.76	14	21780	84701	32407031
Sickle cell disease	22.58	14.76	7	21787	148	32491584
Sleep disorder	22.40	14.76	53	21741	26699	32465033
Renal tubular acidosis	22.35	14.76	15	21779	2017	32489715
Liver transplant	22.13	14.76	17	21777	2823	32488909
Hepatomegaly	22.11	14.76	31	21763	10426	32481306
Blood alkaline phosphatase increased	22.03	14.76	59	21735	32073	32459659
Nephrolithiasis	21.62	14.76	53	21741	27301	32464431
Oral candidiasis	21.59	14.76	33	21761	11994	32479738
Liver disorder	21.57	14.76	58	21736	31596	32460136
Nasopharyngitis	21.38	14.76	8	21786	63779	32427953
Tubulointerstitial nephritis	21.18	14.76	43	21751	19534	32472198
Back pain	21.14	14.76	26	21768	111027	32380705
Meningitis tuberculous	21.11	14.76	10	21784	687	32491045
Pulmonary oedema	21.02	14.76	3	21791	46264	32445468
Hepatic function abnormal	21.00	14.76	72	21722	44768	32446964
Influenza	20.87	14.76	3	21791	46011	32445721
Limb deformity	20.73	14.76	9	21785	504	32491228
Blood pressure increased	20.54	14.76	14	21780	79340	32412392
Hypercholesterolaemia	20.49	14.76	26	21768	7948	32483784
Polyneuropathy chronic	20.47	14.76	5	21789	41	32491691
Hospitalisation	20.43	14.76	4	21790	48967	32442765
Chronic obstructive pulmonary disease	20.30	14.76	4	21790	48749	32442983
Strabismus congenital	20.26	14.76	5	21789	43	32491689
Nodular regenerative hyperplasia	20.15	14.76	10	21784	761	32490971
Synostosis	19.95	14.76	6	21788	114	32491618
Mitochondrial myopathy	19.89	14.76	7	21787	222	32491510
Syphilis	19.33	14.76	9	21785	594	32491138
Amylase increased	19.25	14.76	22	21772	6033	32485699
Blood oestrogen decreased	19.23	14.76	4	21790	14	32491718
Toxoplasma serology positive	19.01	14.76	4	21790	15	32491717
Korsakoff's syndrome	18.93	14.76	3	21791	0	32491732
Interstitial lung disease	18.88	14.76	10	21784	64991	32426741
Congenital eyelid malformation	18.84	14.76	5	21789	59	32491673
Hydrops foetalis	18.77	14.76	7	21787	263	32491469
Product use issue	18.75	14.76	6	21788	52771	32438961
Osteoporotic fracture	18.68	14.76	11	21783	1177	32490555
Product use in unapproved indication	18.14	14.76	19	21775	87185	32404547
C-reactive protein increased	17.94	14.76	5	21789	48097	32443635
Fat redistribution	17.86	14.76	6	21788	165	32491567
Neck deformity	17.86	14.76	5	21789	73	32491659
Platelet count decreased	17.73	14.76	31	21763	114560	32377172
Disease risk factor	17.61	14.76	4	21790	23	32491709
Lipohypertrophy	17.45	14.76	7	21787	321	32491411
Cardiac failure congestive	17.08	14.76	19	21775	84833	32406899
Drug screen false positive	17.04	14.76	9	21785	780	32490952
Hepatic steatosis	16.94	14.76	35	21759	16098	32475634
Elbow synostosis	16.94	14.76	4	21790	28	32491704
Blood cholesterol increased	16.88	14.76	37	21757	17720	32474012
Congenital bowing of long bones	16.81	14.76	4	21790	29	32491703
Cleft lip and palate	16.58	14.76	7	21787	366	32491366
Liver injury	16.53	14.76	32	21762	14042	32477690
Congenital tuberculosis	16.47	14.76	4	21790	32	32491700
Pneumocystis jirovecii pneumonia	16.47	14.76	38	21756	18832	32472900
Blood phosphorus decreased	16.46	14.76	15	21779	3151	32488581
Eyelid ptosis congenital	16.25	14.76	5	21789	103	32491629
Neuropsychiatric syndrome	16.16	14.76	5	21789	105	32491627
Porphyria acute	16.07	14.76	5	21789	107	32491625
Beta 2 microglobulin urine increased	15.98	14.76	5	21789	109	32491623
Meconium ileus	15.95	14.76	4	21790	37	32491695
Splenomegaly	15.90	14.76	32	21762	14445	32477287
Pneumonia aspiration	15.88	14.76	4	21790	41152	32450580
Cerebral toxoplasmosis	15.86	14.76	11	21783	1561	32490171
Disease progression	15.84	14.76	21	21773	86841	32404891
Oesophageal candidiasis	15.69	14.76	17	21777	4397	32487335
Trisomy 18	15.66	14.76	6	21788	243	32491489
Product dose omission issue	15.64	14.76	28	21766	102547	32389185
Castleman's disease	15.58	14.76	4	21790	41	32491691
Viraemia	15.54	14.76	10	21784	1253	32490479
Extrapulmonary tuberculosis	15.41	14.76	5	21789	123	32491609
Hepatic necrosis	15.35	14.76	16	21778	3959	32487773
Optic disc haemorrhage	15.24	14.76	4	21790	45	32491687
Fibrous histiocytoma	15.22	14.76	5	21789	128	32491604
Transaminases increased	15.22	14.76	44	21750	24984	32466748
Pain in extremity	15.13	14.76	36	21758	118865	32372867
Protein S deficiency	15.12	14.76	5	21789	131	32491601
Inappropriate schedule of product administration	14.93	14.76	6	21788	45819	32445913
Subacute sclerosing panencephalitis	14.93	14.76	4	21790	49	32491683
Hereditary optic atrophy	14.77	14.76	3	21791	9	32491723
Premature baby	14.76	14.76	36	21758	18482	32473250

Pharmacologic Action:

Source	Code	Description
ATC	J05AG03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors
ATC	J05AR06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
ATC	J05AR11	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
FDA MoA	N0000009948	Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT	N0000175460	Non-Nucleoside Analog
FDA EPC	N0000175463	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D065695	Cytochrome P-450 CYP2B6 Inducers
MeSH PA	D065689	Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA	D065688	Cytochrome P-450 CYP2C9 Inhibitors
MeSH PA	D065701	Cytochrome P-450 CYP3A Inducers
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors
FDA MoA	N0000187064	Cytochrome P450 2B6 Inducers
FDA MoA	N0000190118	Cytochrome P450 3A Inducers
CHEBI has role	CHEBI:36044	anti-virus drug
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitor

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Prevention of HIV Infection after Exposure	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Hypophosphatemia	contraindication	4996001
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Depressive disorder	contraindication	35489007
Fanconi syndrome	contraindication	40488004	DOID:1062
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Aggressive behavior	contraindication	61372001
Chronic type B viral hepatitis	contraindication	61977001
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Chronic hepatitis C	contraindication	128302006
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Paranoid disorder	contraindication	191667009
Steatosis of liver	contraindication	197321007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Pathological fracture	contraindication	268029009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Osteopenia	contraindication	312894000
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.6	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8592397	Jan. 13, 2024	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8592397	Jan. 13, 2024	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8716264	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9457036	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9744181	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9018192	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9018192	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9545414	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9545414	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
Cholesterol 24-hydroxylase	Enzyme	Q9Y6A2	CP46A_HUMAN		Kd	6.10	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN	INHIBITOR	IC50	4.76	IUPHAR
Reverse transcriptase/RNaseH	Enzyme		Q72547_9HIV1	INHIBITOR	Ki	8.52	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1A2	INHIBITOR	IC50	8.30	WOMBAT-PK
Reverse transcriptase	Enzyme		Q9WKE8_9HIV1		IC50	8.89	CHEMBL
Reverse transcriptase protein	Unclassified		Q9WJQ2_9HIV1		Ki	8.07	CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	Unclassified		Q6QLK5_9HIV1		IC50	8.46	CHEMBL

External reference:

ID	Source
4021133	VUID
N0000148587	NUI
D00896	KEGG_DRUG
4021133	VANDF
C0674428	UMLSCUI
CHEBI:119486	CHEBI
EFZ	PDB_CHEM_ID
CHEMBL223228	ChEMBL_ID
DB00625	DRUGBANK_ID
C098320	MESH_SUPPLEMENTAL_RECORD_UI
64139	PUBCHEM_CID
11287	IUPHAR_LIGAND_ID
7718	INN_ID
JE6H2O27P8	UNII
195084	RXNORM
11884	MMSL
210786	MMSL
7492	MMSL
d04355	MMSL
007651	NDDF
116078005	SNOMEDCT_US
387001004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0470	CAPSULE, GELATIN COATED	50 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0474	CAPSULE, GELATIN COATED	200 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0510	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5234	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2233	TABLET, FILM COATED	600 mg	ORAL	ANDA	26 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	15584-0101	TABLET, FILM COATED	600 mg	ORAL	NDA	34 sections
Efavirenz	Human Prescription Drug Label	1	31722-504	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	33342-138	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, emtricitabine and tenofovir disoproxil fumarate	Human Prescription Drug Label	3	42385-915	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	42385-928	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	42385-929	TABLET, FILM COATED	400 mg	ORAL	ANDA	30 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	42543-889	TABLET	600 mg	ORAL	ANDA	26 sections
SYMFI LO	HUMAN PRESCRIPTION DRUG LABEL	3	49502-425	TABLET, FILM COATED	400 mg	ORAL	NDA	32 sections
SYMFI	HUMAN PRESCRIPTION DRUG LABEL	3	49502-475	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	51407-382	TABLET	600 mg	ORAL	ANDA	26 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	53808-0208	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4668	TABLET, FILM COATED	600 mg	ORAL	NDA	29 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	54868-5643	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Atripla Access	HUMAN PRESCRIPTION DRUG LABEL	3	61958-1601	TABLET, FILM COATED	600 mg	ORAL	EXPORT ONLY	34 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	64380-889	TABLET	600 mg	ORAL	ANDA	18 sections
Efavirenz	Human Prescription Drug Label	1	64980-406	CAPSULE	50 mg	ORAL	ANDA	29 sections
Efavirenz	Human Prescription Drug Label	1	64980-407	CAPSULE	200 mg	ORAL	ANDA	29 sections
Efavirenz	Human Prescription Drug Label	1	65862-049	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz	Human Prescription Drug Label	1	65862-104	CAPSULE	50 mg	ORAL	ANDA	29 sections
Efavirenz	Human Prescription Drug Label	1	65862-105	CAPSULE	100 mg	ORAL	ANDA	29 sections
Efavirenz	Human Prescription Drug Label	1	65862-106	CAPSULE	200 mg	ORAL	ANDA	29 sections
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	65862-497	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
efavirenz, emtricitabine and tenofovir disoproxil fumarate	HUMAN PRESCRIPTION DRUG LABEL	3	69097-210	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	69097-301	TABLET, FILM COATED	600 mg	ORAL	ANDA	26 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	70518-0341	TABLET, FILM COATED	600 mg	ORAL	NDA	33 sections